Nordic Life Science 1
TOP STORIES ACQU I SITIONS // AGREEMENTS // COLLA
BORATIONS Jens Lindberg, CEO, Medivir “Agreements, such as this are a core component of Medivir’s corporate mission and business model.” AI Lundbeck in collaboration with OpenAI The two companies will explore AI-driven use cases across research, development, and commercial functions. BY DEPLOYING of ChatGPT Enterprise throughout its global workforce, Lundbeck will empower employees with AI capabilities designed to accelerate discovery, enhance decision-making, and drive unprecedented efficiency, it states. “By integrating AI into our BIOTECH MEDIVIR IN LICENSING AGREEMENT WITH BIOSSIL Biossil will receive global, exclusive development rights for remetinostat, a clinical-stage topical HDAC inhibitor. SHOULD REMETINOSTAT be successfully developed and approved, the terms of the agreement entitle Medivir to receive payments up to a total of approximately USD 60 million, in addition to mid-single-digit royalties on future net sales. “Agreements, such as this are a core component of Medivir’s corporate mission and business model,” says Jens Lindberg, CEO, Medivir. Remetinostat has shown positive phase-2 data in basal cell carcinoma as well as cutaneous T-cell lymphoma. Biossil is a Torontobased AI-native drug developer focused on developing novel therapies for heterogenous diseases. NLS daily processes, we’re unlocking new levels of efficiency and innovation, bringing science and technology together to improve outcomes for people living with brain disorders,” says Claus Thomsen, SVP, Global IT, Lundbeck. Lundbeck has previously announced strategic partnerships with the Danish Centre for AI Innovation – focused on leveraging the Gefion AI supercomputer – and Iambic Therapeutics to advance the use of AI in drug discovery. NLS Lundbeck headquarters, Valby, Denmark USD 50 BILLION … … is AstraZeneca to invest in US medicines manufacturing and R&D over the next five years. 10 | NORDICLIFESCIENCE.ORG PHOTO PETER EILERTSEN